Ziccum AB Logo

Ziccum AB

ZICC | ST

Overview

Corporate Details

ISIN(s):
SE0011415595 (+3 more)
LEI:
5493005TADJBZHXP0U27
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ziccum AB develops and licenses its proprietary drying technology, LaminarPace®. This platform uses mass transfer at ambient temperatures to formulate sensitive biologics and vaccines into thermostable, particle-engineered dry powders. The process avoids heat-related degradation, preserving the substance's efficacy and eliminating the need for complex cold chain logistics. The resulting powders are also suitable for novel administration routes. Ziccum's business model is focused on entering into license agreements and technology transfers with major pharmaceutical and biotherapeutic companies to integrate its technology into their product development and manufacturing.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ziccum AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ziccum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ziccum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-13 Ann Gidner Other Buy 14,000 8,381.80 SEK

Peer Companies

Company Country Ticker View
FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland FARN
Fluicell AB Logo
Developing bioprinted tissues for regenerative medicine and advanced drug screening.
Sweden FLUI
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark FLUO
FUSION ANTIBODIES PLC Logo
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
United Kingdom FAB
FUTURA MEDICAL PLC Logo
Develops topical sexual health gels, including a fast-acting, over-the-counter ED treatment.
United Kingdom FUM
Gabather AB Logo
Clinical-stage pharma developing GABAA therapeutics for neuropsychiatric disorders.
Sweden GABA
GEIGER COUNTER LIMITED Logo Jersey GCL
Geneuro Logo
Develops HERV-targeting treatments for neurodegenerative and autoimmune diseases.
Switzerland GEM
GENFIT Logo
Biopharma firm developing therapies & diagnostics for rare and severe liver diseases.
France GNFT
GENFLOW BIOSCIENCES PLC Logo
Developing gene therapies to target the aging process in humans and dogs.
United Kingdom GENF